Alexion: Analysts Raise Their Target Prices
As of April 12, 2018, 18 analysts gave a “buy” or “strong buy” recommendation on Alexion stock, while one analyst gave a “hold” recommendation.
WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.
Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
Acquiring Wilson Therapeutics is expected to be a strategic fit for Alexion. Alexion is focused on developing life-transforming rare disease therapies.
On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders.
On March 27, 2018, GlaxoSmithKline (GSK) announced an agreement with Novartis (NVS) to buy Novartis’s stake in their consumer healthcare joint venture.
The news that five patients on Roche’s (RHHBY) hemophilia drug Hemlibra died triggered the stock to decline 2% on March 28, 2018.
On April 3, 2018, Roche (RHHBY) announced that Alecensa was approved in Switzerland as a first-line treatment for ALK-positive NSCLC.
On April 5, 2018, Roche’s (RHHBY) MS (multiple sclerosis) drug Ocrevus was denied recommendation by NICE.
On April 6, 2018, Incyte (INCY) stock fell nearly 20%, triggered by news of the failure of the clinical trial for its skin cancer drug.